Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ADP-A2M4CD8 T cells with or without nivolumab in recurrent ovarian cancer
2022-003176-16Phase 2Active
- Sponsor
- Adaptimmune Therapeutics
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer comparing ADP-A2M4CD8 monotherapy with ADP-A2M4CD8 + Opdivo (2 arms). Primary endpoint: Objective response rate (ORR). Started Dec 2022; status: active.
02
Drugs
ADP adoptive cell therapynivolumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2022-003176-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003176-16.